Affiliated to research
Anna Lantz (former Wallerstedt)
Anna Lantz work as a clinically active urologist at the Department of Urology, Karolinska University Hospital Solna, focusing on detection and treatment of prostate cancer. She combines her clinical work with independent research at Karolinska Institutet.
Anna Lantz defended her thesis "Outcomes after surgical treatment of localized prostate cancer with focus on urinary incontinence and short term complications" in March 2015 at Karolinska Institutet. In 2016 to 2018 she undertook postdoctoral studies at Department of Medical Epidemiology and Biostatistics within the STHLM-studies with focus on improved detection of prostate cancer, setting up the STHLM3AS trial as Principal Investigator. During 2019-2020 Anna Lantz undertook international postdoctoral studies at Icahn School of Medicine, Mount Sinai Hospital in New York.
LAPPRO-trial evaluating functional and oncological outcomes after prostate cancer surgery
- The overarching aim of Anna Lantz research has been to improve patient care for men with prostate cancer. Initially the focus was on outcomes after prostate cancer surgery, evaluating functional outcomes, such as incontinence, erectile dysfunction and quality of life after radical prostatectomy within the Karolinska University Hospital radical prostatectomy cohort and the LAPPRO-trial a multicentre, prospective controlled trial of men who underwent radical prostatectomy between 2008 and 2011 (n=4003), including men from 14 hospitals in Sweden.
Principal Investigator for STHLM3AS and STHLM3AS-NorDCaP
- The latest years the focus of Anna Lantz research has been on men living with a low-risk prostate cancer. As Principal Investigator for the two prospective trials STHLM3AS and STHLM3AS-NorDCaP, with the aim to improve the way we select and monitor men with low-risk prostate cancer, Anna Lantz hypothesize that the proposed research will improve AS for men with clinically insignificant prostate cancer through a new surveillance protocol including state of the art risk prediction models in combination with MRI and targeted biopsies and that it would lead to equally safe monitoring as the conventional protocol, but minimizing the numbers of prostate biopsies.
Studies within the STHLM0 database
- Using the population-based cohort STHLM0, Anna Lantz has been involved in several studies evaluating the effect of drugs and diseases on the risk of being diagnosed with prostate cancer. For example, in 2018 she performed a large population-based historical prospective study using data from STHLM0 and found a reduced risk of prostate cancer among 5-ARI users.
Mount Sinai Prostate Cancer Cohort and Multicenter MRI-database
- Together with collaborators at Mount Sinai Hospital, New York, Anna Lantz has been focusing on the predictive value of MRI for disease detection within different subgroups. For example, evaluating the performance of staging mpMRI in African American men compared to Caucasian American men. Through the collaboration, Anna Lantz has been involved in creating a multicenter MRI-database with data from 5 countries, containing 3700 men with prostate cancer that has underwent MRI and targeted biopsies.
2018-2019 Course responsible in urology for medical students, KI
2017- Teacher for medical students at the Department of Urology, KS Solna
2019-2020 Postdoc (Icahn School of Medicine, Mount Sinai Hospital, New York)
2016-2018 Postdoc (Department of Medical Epidemiology and Biostatistics, KI)
2015 Ph.D. (Department of Molecular Medicine and Surgery, KI)
2008 M.D. (KI)
Academic honours, awards and prizes
2018- SLL Postdoc
2011-2016 Research Resident
2011 26th Annual EAU Congress in Vienna, Best Poster Presentation Award